Dry Eye

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Marguerite McDonald, MD, Eric Donnenfeld, MD, Tracy Swartz, OD, MS, FAAO, and Crystal Brimer, OD, FAAO, discuss a number of topics pertaining to Dry Eye including the diagnosis and clinical manifestations, traditional, treatment options, and the potential new agents in the horizon.

Study shows improvements in signs, symptoms after 3 months of treatment

Cynthia Matossian, MD, FACS, advises on how ophthalmologists can start performing a better diagnosis of ocular surface disease in three simple steps.

Fast-acting efficacious options are key to treating acute inflammation

Cynthia Matossian, MD, FACS, explains why she believes if ophthalmologists consistently evaluate the ocular surface, tear film and lid margins—and treat any problems that we find—surgical outcomes will improve.

Surveyed patients express dissatisfaction with efficacy of eye drops.